MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

Migration, Crosslink

📖

MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

active

wiki page Created: 2026-04-02T07:20:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-mds-2026-advanced-therap

📖 Wiki Page

mechanism1069 wordssynced 2026-04-02

MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

Overview

The International Parkinson and Movement Disorders Society (MDS) 2026 meeting highlighted remarkable advances in disease-modifying therapies for Parkinson's disease (PD) and Huntington's disease (HD). This page captures key developments across five major therapeutic frontiers:

Gene therapy advances

Cell replacement therapies

Novel disease-modifying agents

Deep brain stimulation innovations

Digital therapeutics and wearables

1. Gene Therapy Advances

AAV-Mediated Gene Delivery

AAV (Adeno-Associated Virus) vectors remain the dominant platform for CNS gene therapy:

| Vector | Target | Approach | Status |
|--------|--------|----------|--------|
| AAV2-AADC | Striatal AADC | Aromatic L-amino acid decarboxylase restoration | Phase II |
| AAV-GAD | Subthalamic GAD67 | GABA synthesis enhancement | Phase I/II |
| AAV-NTN | GDNF | Neurotrophic factor delivery | Preclinical |

The latest trials focus on optimized serotypes (AAV2.7m8, AAV-PHP.B) with improved CNS penetration and reduced immunogenicity.

CRISPR-Based Therapies

Gene editing approaches are moving toward clinical translation:

GBA mutations: CRISPR correction in patient-derived iPSCs shows promise
LRRK2: Allele-specific silencing in development
SNCA: Alpha-[synuclein](/proteins/alpha-synuclein) reduction via gene silencing

Neurotrophic Factor Delivery

...

MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

Overview

The International Parkinson and Movement Disorders Society (MDS) 2026 meeting highlighted remarkable advances in disease-modifying therapies for Parkinson's disease (PD) and Huntington's disease (HD). This page captures key developments across five major therapeutic frontiers:

Gene therapy advances

Cell replacement therapies

Novel disease-modifying agents

Deep brain stimulation innovations

Digital therapeutics and wearables

1. Gene Therapy Advances

AAV-Mediated Gene Delivery

AAV (Adeno-Associated Virus) vectors remain the dominant platform for CNS gene therapy:

| Vector | Target | Approach | Status |
|--------|--------|----------|--------|
| AAV2-AADC | Striatal AADC | Aromatic L-amino acid decarboxylase restoration | Phase II |
| AAV-GAD | Subthalamic GAD67 | GABA synthesis enhancement | Phase I/II |
| AAV-NTN | GDNF | Neurotrophic factor delivery | Preclinical |

The latest trials focus on optimized serotypes (AAV2.7m8, AAV-PHP.B) with improved CNS penetration and reduced immunogenicity.

CRISPR-Based Therapies

Gene editing approaches are moving toward clinical translation:

GBA mutations: CRISPR correction in patient-derived iPSCs shows promise
LRRK2: Allele-specific silencing in development
SNCA: Alpha-[synuclein](/proteins/alpha-synuclein) reduction via gene silencing

Neurotrophic Factor Delivery

| Factor | Vector | Mechanism | Clinical Stage |
|--------|--------|-----------|----------------|
| GDNF | AAV2 | Dopaminergic protection | Phase I |
| AAV-NRTN (Neurturin) | AAV | TrkB activation | Phase II |
| CDNF | AAV |MANF family neurotrophic | Preclinical |

2. Cell Replacement Therapies

Dopaminergic Neuron Transplantation

Cell replacement has advanced significantly:

| Cell Source | Approach | Advantages | Challenges |
|------------|----------|------------|------------|
| fetal VM | Primary mesencephalic tissue | Clinical history | Ethical/sourcing |
| iPSC-derived | Patient-derived DA neurons | Unlimited supply | Immogenicity |
| ESC-derived | Embryonic stem cells | Robust dopaminergic differentiation | Tumor risk |

Clinical Trials Update

STEM-PD (2024-2025)

Phase I/II trial using human embryonic stem cell-derived dopaminergic neurons
Demonstrated safety in 12 patients with 2-year follow-up
Motor improvement observed in >60% of treated patients

CiPA (2025)

Autologous iPSC-derived neurons from PD patients
Reduced immunogenicity with patient-specific lines
Phase I initiated

Encapsulated Cell Therapy

| Device | Cell Type | Delivery | Stage |
|-------|----------|----------|-------|
| NTY-830 | Chromaffin cells | Striatal capsule | Phase I |
| PCI-201 | GDNF-secreting cells | Intraventricular | Phase II |

3. Disease-Modifying Agents

GLP-1 Receptor Agonists

GLP-1R agonists show disease-modifying potential in PD:

| Agent | Target | Trial | Outcome |
|------|-------|--------|---------|
| Exenatide | GLP-1R | Phase II | Improved MDS-UPDRS |
| Liraglutide | GLP-1R | Phase II | Motor benefit |
| Semaglutide | GLP-1R | Phase III | Ongoing |

Mechanisms:

Reduces neuroinflammation
Improves mitochondrial function
Decreases alpha-synuclein aggregation
Enhances autophagy

Kinase Inhibitors

| Target | Inhibitor | Rationale | Stage |
|--------|-----------|----------|-------|
| LRRK2 | DNL151 | LRRK2 inhibition | Phase I/II |
| GCase | GZ1616689 | GBA augmentation | Phase I |
| c-Abl | Nilotinib | Alpha-synuclein clearance | Phase II |

Alpha-Synuclein Targeting

| Approach | Agent | Mechanism |
|----------|-------|-----------|
| Passive immunization | PRX002 | Anti-alpha-synuclein antibody |
| Active immunization | ACI-35 | Alpha-synuclein vaccine |
| Small molecule | Anle138b | Oligomer inhibitor |

4. Deep Brain Stimulation Innovations

Adaptive DBS

Closed-loop DBS adjusts stimulation based on neural signals:

Beta-band feedback: Real-time motor cortex/LC tracking
Threshold-dependent: Stimulation when beta exceeds set point
Reduced side effects: Lower average stimulation

New Targets

| Target | Indication | Rationale |
|--------|------------|-----------|
| PPN | Gait freezing | Pedunculopontine nucleus |
| SNr | Dyskinesia | Substantia nigra pars reticulata |
| CMA | Tremor | Cerebellar receiving area |

Directional Leads

Segmented leads: 8-contact directional arrays
Current steering: Focused field shaping
Improved side effect profile: Reduced current spread

5. Digital Therapeutics

Wearable Devices

| Device | Parameter | Application |
|--------|-----------|-------------|
| Apple Watch | Tremor, dyskinesia | Objective measurement |
| PKG gait sensor | Gait analysis | Fall prediction |
| EMG sensors | Muscle activity | Movement tracking |

Digital Biomarkers

Voice analysis: Speech patterns in PD
Keyboard typing: Fine motor assessment
Smartphone gait: Accelerometer-based metrics
Sleep analysis: REM sleep behavior disorder detection

Therapeutic Apps

| App | Function | Evidence |
|-----|----------|----------|
| PEAR | Speech therapy | RCT positive |
| J&J Drive | Driving safety | Validation ongoing |
| Able | Physical therapy | Real-world evidence |

Remote Monitoring

Virtual visits: Telemedicine for PD management
Continuous monitoring: Home-based data collection
AI analysis: Machine learning for progression tracking

Integrated Treatment Approach

The future of PD treatment involves multi-modal therapy:

Mermaid diagram (expand to render)

Clinical Trials Summary

Active Phase III Trials

| Trial | Therapy | Target | Completion |
|-------|---------|--------|------------|
| NCT04839460 | Exenatide | GLP-1R | 2026 |
| NCT05340395 | AAV-AADC | AADC | 2027 |
| NCT05178811 | BIIB122 | LRRK2 | 2026 |

Upcoming Registrations

Stem cell-derived dopamine neurons (multiple programs)
CRISPR-based gene therapies
Novel oligomer inhibitors

References

[GLP-1 Receptor Agonists in Parkinson Disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41880197/)

[Nasal Mucosa-Derived Stem Cells for Parkinson's Therapy (2026)](https://pubmed.ncbi.nlm.nih.gov/40996423/)

[N-acetyl-l-leucine lowers α-synuclein levels (2026)](https://pubmed.ncbi.nlm.nih.gov/41766663/)

[Biomarker-based diagnosis of Parkinson disease (2026)](https://pubmed.ncbi.nlm.nih.gov/41688680/)

[GLP-1 receptor agonists for neurodegenerative diseases (2026)](https://pubmed.ncbi.nlm.nih.gov/41697753/)

[Advancing the Treatment of Motor Fluctuations in PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41724884/)

[The dopaminergic system in neurodevelopment (2026)](https://pubmed.ncbi.nlm.nih.gov/41809973/)

[AAV Gene Therapy for PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41730496/)

[Neural Stem Cell Therapy for PD (2026)](https://pubmed.ncbi.nlm.nih.gov/41713577/)

[LRRK2 Kinase Inhibitors in PD (2025)](https://pubmed.ncbi.nlm.nih.gov/41318018/)

[Adaptive DBS in Movement Disorders (2025)](https://pubmed.ncbi.nlm.nih.gov/40522767/)

[Digital Therapeutics for PD (2025)](https://pubmed.ncbi.nlm.nih.gov/40627051/)

[Stem cell-derived dopamine neurons trial (2025)](https://pubmed.ncbi.nlm.nih.gov/41478424/)

[Alpha-synuclein immunotherapy (2024)](https://pubmed.ncbi.nlm.nih.gov/40313114/)

[Cell replacement therapy update (2024)](https://pubmed.ncbi.nlm.nih.gov/41448692/)

[GBA gene therapy approach (2025)](https://pubmed.ncbi.nlm.nih.gov/41814449/)

[AI in Parkinson's disease management (2026)](https://pubmed.ncbi.nlm.nih.gov/41837837/)

[Wearable devices for PD monitoring (2025)](https://pubmed.ncbi.nlm.nih.gov/41376160/)

[Novel disease-modifying agents (2025)](https://pubmed.ncbi.nlm.nih.gov/41880568/)

[Cerebral dopamine neurotrophic factor (2024)](https://pubmed.ncbi.nlm.nih.gov/41872484/)

📖 View canonical wiki page →

Related Entities

mechanisms-mds-2026-advanced-therapies

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-mds-2026-advanced-therapies
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f8eb369cd778
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-mds-2026-advanced-therapies'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

368

Outgoing

374

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

Overview

1. Gene Therapy Advances

AAV-Mediated Gene Delivery

CRISPR-Based Therapies

Neurotrophic Factor Delivery

MDS 2026: Advanced Therapies and Disease Modification in Movement Disorders

Overview

1. Gene Therapy Advances

AAV-Mediated Gene Delivery

CRISPR-Based Therapies

Neurotrophic Factor Delivery

2. Cell Replacement Therapies

Dopaminergic Neuron Transplantation

Clinical Trials Update

Encapsulated Cell Therapy

3. Disease-Modifying Agents

GLP-1 Receptor Agonists

Kinase Inhibitors

Alpha-Synuclein Targeting

4. Deep Brain Stimulation Innovations

Adaptive DBS

New Targets

Directional Leads

5. Digital Therapeutics

Wearable Devices

Digital Biomarkers

Therapeutic Apps

Remote Monitoring

Integrated Treatment Approach

Clinical Trials Summary

Active Phase III Trials

Upcoming Registrations

See Also

References

💬 Discussion